skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk

Review

(2371) Views  (791) Full article downloads

Authors: Naila Goldenberg, Charles Glueck

Published Date April 2009 Volume 2009:5 Pages 369 - 376
DOI: http://dx.doi.org/10.2147/VHRM.S3241

Naila Goldenberg1,2, Charles Glueck1

1Cholesterol and Metabolism Center of Jewish Hospital, Cincinnati, Ohio, USA; 2University of Cincinnati, Division of Endocrinology and Metabolism, Cincinnati, Ohio, USA

Abstract: Statins became available for the treatment of hypercholesterolemia in 1987. Multiple, well-designed, placebo-controlled, double-blind studies revealed that each 1% reduction in serum cholesterol level was associated with about 1% reduction in risk of cardiovascular events. Low-density lipoprotein (LDL) cholesterol reduction to less than 78 mg/dL may be associated with reduction of atheroma burden. Patients with high levels of high specificity C-reactive protein and having LDL cholesterol less than 3.4 mmol/L (130 mg/dL) in primary prevention settings benefited from aggressive LDL cholesterol reduction with rosuvastatin over a 2-year period. However, in real life practice, about half of patients who are prescribed statins discontinue the medication by the end of the year. Medication adherence is lower in younger patients, women, and absence of known coronary heart disease. Personal features of the prescribing physician and dispensing pharmacies also affect patients’ compliance. More studies are needed to evaluate if “compliance packets” would benefit patients in a real life situation.

Keywords: cardiovascular risk, statin, goal attainment, primary prevention, secondary prevention








Readers of this article also read:

Efficacy and safety of rosuvastatin in the management of dyslipidemia
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Reducing morbidity and mortality in high risk patients with statins
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Coronary computed tomographic angiography (CCTA) in community hospitals: “current and emerging role”
Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia
Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits
Current state of cardiac rehabilitation in Germany: patient characteristics, risk factor management and control status, by education level
Barriers to cardiovascular risk prevention and management in Germany – an analysis of the EURIKA study
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University